No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C

Ziad Kronfol, Heather J. Litman, Carla Back-Madruga, Linas A. Bieliauskas, Karen L. Lindsay, Anna S. Lok, Robert J. Fontana

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Peginterferon and ribavirin treatment of chronic hepatitis C (CHC) is frequently associated with dose-limiting neuropsychiatric toxicity. The purpose of this study is to determine whether prolonged administration of low-dose peginterferon-α2a is associated with an increase in the rate and severity of depression compared to untreated controls. Methods: 129 non-responders to full-dose peginterferon and ribavirin treatment were randomized to low-dose maintenance treatment with peginterferon-α2a 90 μg/week or no treatment for 3.5 years. Depression was assessed using the Beck Depression Inventory (BDI-II) and the Composite International Diagnostic Interview (CIDI) at baseline and at 12, 24, 36, and 48 months. "Clinical depression" was defined as BDI-II ≥ 11 and/or meeting DSM-IV criteria for major depression on the CIDI. Serial cortisol and serotonin plasma concentrations were obtained in a subgroup of patients. Results: Rates of clinical depression did not significantly differ over time or between treatment groups. Baseline clinical depression was the only significant predictor of clinical depression over time (p < 0.001). Rates of clinical depression were also significantly higher in patients experiencing liver disease progression (p = 0.016). Antidepressant use did not significantly differ between groups. Adjusted whole blood serotonin levels dropped significantly over time (p = 0.04), but there was no group by time effect. Limitations: Lack of significant group differences in antidepressant use does not completely preclude significant mood changes masked by antidepressants. Results may differ in treatment naïve CHC patients or in those receiving full-dose peginterferon. Conclusions: Prolonged low-dose peginterferon-α2a treatment is not associated with an increase in the frequency or severity of clinical depression in prior non-responder patients with chronic hepatitis C.

Original languageEnglish
Pages (from-to)205-212
Number of pages8
JournalJournal of Affective Disorders
Volume129
Issue number1-3
DOIs
Publication statusPublished - Mar 2011
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Maintenance
Depression
Antidepressive Agents
Ribavirin
Therapeutics
Serotonin
Interviews
Diagnostic and Statistical Manual of Mental Disorders
Disease Progression
Hydrocortisone
Liver Diseases
Equipment and Supplies

Keywords

  • Beck Depression Inventory
  • Cytokines
  • Interferon
  • Mood states
  • Neuropsychiatric toxicity

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Kronfol, Z., Litman, H. J., Back-Madruga, C., Bieliauskas, L. A., Lindsay, K. L., Lok, A. S., & Fontana, R. J. (2011). No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. Journal of Affective Disorders, 129(1-3), 205-212. https://doi.org/10.1016/j.jad.2010.09.010

No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. / Kronfol, Ziad; Litman, Heather J.; Back-Madruga, Carla; Bieliauskas, Linas A.; Lindsay, Karen L.; Lok, Anna S.; Fontana, Robert J.

In: Journal of Affective Disorders, Vol. 129, No. 1-3, 03.2011, p. 205-212.

Research output: Contribution to journalArticle

Kronfol, Ziad ; Litman, Heather J. ; Back-Madruga, Carla ; Bieliauskas, Linas A. ; Lindsay, Karen L. ; Lok, Anna S. ; Fontana, Robert J. / No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. In: Journal of Affective Disorders. 2011 ; Vol. 129, No. 1-3. pp. 205-212.
@article{44db008bc581460fb6cd46bca41ce94e,
title = "No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C",
abstract = "Background: Peginterferon and ribavirin treatment of chronic hepatitis C (CHC) is frequently associated with dose-limiting neuropsychiatric toxicity. The purpose of this study is to determine whether prolonged administration of low-dose peginterferon-α2a is associated with an increase in the rate and severity of depression compared to untreated controls. Methods: 129 non-responders to full-dose peginterferon and ribavirin treatment were randomized to low-dose maintenance treatment with peginterferon-α2a 90 μg/week or no treatment for 3.5 years. Depression was assessed using the Beck Depression Inventory (BDI-II) and the Composite International Diagnostic Interview (CIDI) at baseline and at 12, 24, 36, and 48 months. {"}Clinical depression{"} was defined as BDI-II ≥ 11 and/or meeting DSM-IV criteria for major depression on the CIDI. Serial cortisol and serotonin plasma concentrations were obtained in a subgroup of patients. Results: Rates of clinical depression did not significantly differ over time or between treatment groups. Baseline clinical depression was the only significant predictor of clinical depression over time (p < 0.001). Rates of clinical depression were also significantly higher in patients experiencing liver disease progression (p = 0.016). Antidepressant use did not significantly differ between groups. Adjusted whole blood serotonin levels dropped significantly over time (p = 0.04), but there was no group by time effect. Limitations: Lack of significant group differences in antidepressant use does not completely preclude significant mood changes masked by antidepressants. Results may differ in treatment na{\"i}ve CHC patients or in those receiving full-dose peginterferon. Conclusions: Prolonged low-dose peginterferon-α2a treatment is not associated with an increase in the frequency or severity of clinical depression in prior non-responder patients with chronic hepatitis C.",
keywords = "Beck Depression Inventory, Cytokines, Interferon, Mood states, Neuropsychiatric toxicity",
author = "Ziad Kronfol and Litman, {Heather J.} and Carla Back-Madruga and Bieliauskas, {Linas A.} and Lindsay, {Karen L.} and Lok, {Anna S.} and Fontana, {Robert J.}",
year = "2011",
month = "3",
doi = "10.1016/j.jad.2010.09.010",
language = "English",
volume = "129",
pages = "205--212",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C

AU - Kronfol, Ziad

AU - Litman, Heather J.

AU - Back-Madruga, Carla

AU - Bieliauskas, Linas A.

AU - Lindsay, Karen L.

AU - Lok, Anna S.

AU - Fontana, Robert J.

PY - 2011/3

Y1 - 2011/3

N2 - Background: Peginterferon and ribavirin treatment of chronic hepatitis C (CHC) is frequently associated with dose-limiting neuropsychiatric toxicity. The purpose of this study is to determine whether prolonged administration of low-dose peginterferon-α2a is associated with an increase in the rate and severity of depression compared to untreated controls. Methods: 129 non-responders to full-dose peginterferon and ribavirin treatment were randomized to low-dose maintenance treatment with peginterferon-α2a 90 μg/week or no treatment for 3.5 years. Depression was assessed using the Beck Depression Inventory (BDI-II) and the Composite International Diagnostic Interview (CIDI) at baseline and at 12, 24, 36, and 48 months. "Clinical depression" was defined as BDI-II ≥ 11 and/or meeting DSM-IV criteria for major depression on the CIDI. Serial cortisol and serotonin plasma concentrations were obtained in a subgroup of patients. Results: Rates of clinical depression did not significantly differ over time or between treatment groups. Baseline clinical depression was the only significant predictor of clinical depression over time (p < 0.001). Rates of clinical depression were also significantly higher in patients experiencing liver disease progression (p = 0.016). Antidepressant use did not significantly differ between groups. Adjusted whole blood serotonin levels dropped significantly over time (p = 0.04), but there was no group by time effect. Limitations: Lack of significant group differences in antidepressant use does not completely preclude significant mood changes masked by antidepressants. Results may differ in treatment naïve CHC patients or in those receiving full-dose peginterferon. Conclusions: Prolonged low-dose peginterferon-α2a treatment is not associated with an increase in the frequency or severity of clinical depression in prior non-responder patients with chronic hepatitis C.

AB - Background: Peginterferon and ribavirin treatment of chronic hepatitis C (CHC) is frequently associated with dose-limiting neuropsychiatric toxicity. The purpose of this study is to determine whether prolonged administration of low-dose peginterferon-α2a is associated with an increase in the rate and severity of depression compared to untreated controls. Methods: 129 non-responders to full-dose peginterferon and ribavirin treatment were randomized to low-dose maintenance treatment with peginterferon-α2a 90 μg/week or no treatment for 3.5 years. Depression was assessed using the Beck Depression Inventory (BDI-II) and the Composite International Diagnostic Interview (CIDI) at baseline and at 12, 24, 36, and 48 months. "Clinical depression" was defined as BDI-II ≥ 11 and/or meeting DSM-IV criteria for major depression on the CIDI. Serial cortisol and serotonin plasma concentrations were obtained in a subgroup of patients. Results: Rates of clinical depression did not significantly differ over time or between treatment groups. Baseline clinical depression was the only significant predictor of clinical depression over time (p < 0.001). Rates of clinical depression were also significantly higher in patients experiencing liver disease progression (p = 0.016). Antidepressant use did not significantly differ between groups. Adjusted whole blood serotonin levels dropped significantly over time (p = 0.04), but there was no group by time effect. Limitations: Lack of significant group differences in antidepressant use does not completely preclude significant mood changes masked by antidepressants. Results may differ in treatment naïve CHC patients or in those receiving full-dose peginterferon. Conclusions: Prolonged low-dose peginterferon-α2a treatment is not associated with an increase in the frequency or severity of clinical depression in prior non-responder patients with chronic hepatitis C.

KW - Beck Depression Inventory

KW - Cytokines

KW - Interferon

KW - Mood states

KW - Neuropsychiatric toxicity

UR - http://www.scopus.com/inward/record.url?scp=79851511608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79851511608&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2010.09.010

DO - 10.1016/j.jad.2010.09.010

M3 - Article

C2 - 20889211

AN - SCOPUS:79851511608

VL - 129

SP - 205

EP - 212

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 1-3

ER -